false
0000914139
0000914139
2026-03-23
2026-03-23
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 23, 2026
PARKERVISION, INC.
(Exact Name of Registrant as Specified in Charter)
| |
|
|
|
Florida
|
000-22904
|
59-2971472
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
| |
|
|
4446-1A Hendricks Avenue Suite 354, Jacksonville, Florida
|
32207
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
(904) 732-6100
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
| |
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
| |
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
| |
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of Each Class
|
Trading Symbol
|
Name of Each Exchange on Which Registered
|
|
None
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On March 23, 2026, ParkerVision, Inc. (the “Company”) issued a press release which reported financial and operating results for the year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.
The information contained in this Current Report on Form 8-K, including Exhibit 99.1 hereto, has been “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section. The information in this Current Report shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
| Exhibit |
Description |
| 99.1 |
Press Release |
| 104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
|
|
Dated: March 23, 2026
|
|
|
| |
|
PARKERVISION, INC.
|
| |
|
|
| |
|
By /s/ Cynthia French
|
| |
|
Cynthia French
|
| |
|
Chief Financial Officer
|
Exhibit 99.1
ParkerVision Reports Year End 2025 Results
JACKSONVILLE, Fla., March 23, 2026 – ParkerVision, Inc. (OTCQB: PRKR) (“ParkerVision” or the "Company"), a developer and marketer of technologies and products for wireless applications, today announced results for the year ended December 31, 2025.
2025 Summary and Recent Developments
| |
• |
The Court of Appeals for the Federal Circuit ("CAFC") granted the Company's motion for an expedited schedule in its appeal of ParkerVision v. Qualcomm (CAFC case no. 26-1033). The expedited schedule calls for the completion of briefings by both parties by March 23, 2026, with oral arguments scheduled for the next available session thereafter.
|
| |
|
|
| |
|
|
◦ |
The Company is appealing the May 30, 2025 claim construction ruling made by the district court (Middle District of Florida) which led to a stipulation of noninfringement of the Company's receiver patent claims. The district court severed and stayed the remaining transmitter patent claims in the case pending the decision of the appellate court. |
| |
|
|
|
| |
|
|
◦ |
Qualcomm has filed a motion with the CAFC to dismiss the appeal for lack of jurisdiction. The CAFC ordered the parties to address the merits of any jurisdictional issues in their respective briefs, which the parties have done. |
| |
• |
The Company's first patent infringement trials against MediaTek in the Western District of Texas, scheduled to commence on March 20, 2026, has been postponed by the district court, pending resubmission of expert reports and related briefings by the parties. |
| |
|
|
Jeffrey Parker, CEO of ParkerVision, commented, “We began 2025 on the heels of a favorable appellate court ruling in our Qualcomm case that we anticipated would lead to a much-awaited jury trial in 2025. Unfortunately, following the remand from the federal circuit, the district court decided to allow Qualcomm a third chance at claim construction in an over ten-year old, trial-ready case, and furthermore ruled that a 'generating limitation,' which imposes a requirement that does not appear anywhere in the alleged infringing patent specifications or claims, should be added to each of the receiver patent claims currently under appeal. This resulted in a stipulation of noninfringement of our receiver claims and, ultimately, a return to the appellate court. We are pleased that the appellate court granted our motion for an expedited appeal, and we remain optimistic that we will once again receive a favorable decision."
Mr. Parker continued, "Meanwhile, we, along with our litigation team, were in Waco, Texas a week ago anticipating the start of our first of three jury trials against MediaTek. In a pre-trial hearing held just days before scheduled jury selection, the judge requested that our damages expert provide additional support in certain areas of his damages calculations, resulting in a postponement of the trial. The court indicated it would reset a pretrial and trial schedule once the parties have updated the expert reports and related briefings. We have been looking forward to sharing the merits of our case with a jury and are, of course, disappointed that the trial was postponed. However, we feel that the guidance from the court provides us with an opportunity to further strengthen the expert reports for this and all future cases in this district. Despite the delay in the MediaTek case, we still believe that 2026 will be a pivotal year for ParkerVision's patent enforcement activities."
Financial Results
| |
•
|
ParkerVision reported a net loss for the year ended December 31, 2025 of $7.4 million, or $0.06 per common share, compared to a net loss of $14.5 million, or $0.16 per common share for the year ended December 31, 2024.
|
| |
◦ |
The decrease in net loss is primarily the result of changes in the estimated fair value of the Company's contingent payment obligations, partially offset by increases in share-based compensation and other operating expenses.
|
| |
|
|
| |
|
- The Company recognized a gain on the change in fair value of its contingent payment obligations of approximately $0.6 million in 2025, compared to a loss on changes in the fair value of the Company's contingent payment obligations of approximately $9.6 million in 2024. These changes in fair value result from changes in estimated probabilities, amounts and timing of projected future repayments of the Company's contingent payment obligations. The assumptions used in these estimates are highly subjective and may not be reflective of amounts actually repaid in the future which are contingent upon receipt of proceeds from patent enforcement, licensing and other patent-related items. The Company recorded significant increases in the fair value of its contingent payment obligations in 2024, in part due to changes in the probability and timing related to the Qualcomm action following the appellate court's remand of the case back to district court in September 2024 after finding in the Company's favor on all issues. |
| |
|
|
| |
|
- Share-based compensation expense increased $3.0 million from 2024 to 2025, primarily as the result of a $2.5 million one-time noncash charge recognized in 2025 upon the modification of previously issued and fully vested nonqualified share options held by executives and key employees. The modification extended the expiration date of these options from January 2026 to January 2031. All other terms of the options, including the $0.54 exercise price per share, remained unchanged. |
| |
•
|
The Company ended 2025 with $4.4 million in cash and cash equivalents and approximately $2.3 million in working capital.
|
| |
◦ |
In November 2025, the Company completed the sale of 21.2 million shares of its common stock at a price of $0.21 per share in a registered direct offering under its shelf registration for gross proceeds of approximately $4.5 million. |
| |
|
|
| |
◦ |
In March 2026, the Company issued 3.2 million shares of its common stock at a price of $0.21 per share in a registered direct offering under its shelf registration in satisfaction of $0.67 million in upcoming convertible note maturities, thus increasing our available working capital. |
About ParkerVision
ParkerVision, Inc. invents, develops and licenses cutting-edge, proprietary radio-frequency (RF) technologies that enable wireless solution providers to make and sell advanced wireless communication products. ParkerVision is engaged in a number of patent enforcement actions in the U.S. to protect patented rights that it believes are broadly infringed by others. For more information, please visit www.parkervision.com. (PRKR-I)
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements regarding the timing, scheduling, and expected outcomes of current and future legal proceedings; the potential impact and significance of such proceedings; and expectations concerning court and PTAB rulings, trial dates, and pre-trial motions. Forward-looking statements also include estimates and assumptions underlying financial information, including the fair value of contingent payment obligations and the Company’s ability to support ongoing operations and litigation.
These statements are based on current expectations, estimates, projections, and assumptions as of the date of this release, and involve known and unknown risks and uncertainties that could cause actual results to differ materially. Words such as “believe,” “optimistic,” “expect,” “will," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements include these words. Risks and uncertainties that may cause actual results to differ include, among others: adverse developments or delays in legal proceedings; unfavorable court or PTAB decisions or rulings; the loss or unavailability of key expert witnesses; the availability of funding for continued operations and litigation; changes in the legal or regulatory environment; inaccuracies in financial estimates or assumptions; and risks disclosed in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent filings.
Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.
|
|
|
Cindy French
|
|
Chief Financial Officer
|
|
ParkerVision, Inc
|
|
cfrench@parkervision.com
|
|
|
(TABLES FOLLOW)
ParkerVision, Inc.
Balance Sheet Highlights (unaudited)
| |
|
(unaudited)
|
|
|
|
|
|
|
(in thousands)
|
|
December 31, 2025
|
|
|
December 31, 2024
|
|
|
Cash and cash equivalents
|
|
$ |
4,360 |
|
|
$ |
4,918 |
|
|
Prepaid expenses and other current assets
|
|
|
304 |
|
|
|
127 |
|
|
Intangible assets & other noncurrent assets
|
|
|
695 |
|
|
|
834 |
|
|
Total assets
|
|
|
5,359 |
|
|
|
5,879 |
|
| |
|
|
|
|
|
|
|
|
|
Current liabilities
|
|
|
2,409 |
|
|
|
2,408 |
|
|
Contingent payment obligations
|
|
|
46,089 |
|
|
|
46,659 |
|
|
Convertible notes, net of current portion
|
|
|
1,908 |
|
|
|
3,023 |
|
|
Other long-term liabilities
|
|
|
57 |
|
|
|
201 |
|
|
Shareholders’ deficit
|
|
|
(45,104 |
) |
|
|
(46,412 |
) |
|
Total liabilities and shareholders’ deficit
|
|
$ |
5,359 |
|
|
$ |
5,879 |
|
ParkerVision, Inc.
Summary Results of Operations (unaudited)
| |
|
Year Ended
|
|
|
(in thousands, except per share amounts)
|
|
December 31,
|
|
| |
|
2025
|
|
|
2024
|
|
|
Licensing revenue
|
|
$ |
- |
|
|
$ |
- |
|
|
Cost of sales
|
|
|
(199 |
) |
|
|
(229 |
) |
|
Gross margin
|
|
|
(199 |
) |
|
|
(229 |
) |
| |
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses
|
|
|
7,606 |
|
|
|
4,262 |
|
|
Total operating expenses
|
|
|
7,606 |
|
|
|
4,262 |
|
| |
|
|
|
|
|
|
|
|
|
Interest expense and other
|
|
|
(191 |
) |
|
|
(342 |
) |
|
Change in fair value of contingent payment obligations
|
|
|
570 |
|
|
|
(9,639 |
) |
|
Total other income (expense)
|
|
|
379 |
|
|
|
(9,981 |
) |
| |
|
|
|
|
|
|
|
|
|
Net loss
|
|
$ |
(7,426 |
) |
|
$ |
(14,472 |
) |
| |
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per common share
|
|
$ |
(0.06 |
) |
|
$ |
(0.16 |
) |
| |
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding
|
|
|
121,319 |
|
|
|
92,150 |
|
ParkerVision, Inc.
Summary of Cash Flows
(unaudited)
| |
|
Year Ended
|
|
|
(in thousands)
|
|
December 31,
|
|
| |
|
2025
|
|
|
2024
|
|
|
Net cash used in operating activities
|
|
$ |
(5,143 |
) |
|
$ |
(3,216 |
) |
|
Net cash used in investing activities
|
|
|
(61 |
) |
|
|
- |
|
|
Net cash provided by financing activities
|
|
|
4,646 |
|
|
|
5,574 |
|
| |
|
|
|
|
|
|
|
|
|
Net decrease in cash and cash equivalents
|
|
|
(558 |
) |
|
|
2,358 |
|
| |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents - beginning of period
|
|
|
4,918 |
|
|
|
2,560 |
|
| |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents - end of period
|
|
$ |
4,360 |
|
|
$ |
4,918 |
|
